The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitorsMario Mandalà, Daniela Massi, Eliana Rulli et al.|Journal for ImmunoTherapy of Cancer|2019Cited by 68
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international studyMario Mandalà, Paolo A. Ascierto, Paul Lorigan et al.|European Journal of Cancer|2024Cited by 45
The Impact of NUTRItional Status at First Medical Oncology Visit on Clinical Outcomes: The NUTRIONCO StudyMaurizio Muscaritoli, Stefania Gori, Alessandra Modena et al.|Cancers|2023Cited by 27
Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC)Mauro Mansutti, M. Venturini, Giovanna Cavazzini et al.|Journal of Clinical Oncology|2008Cited by 3